1118a
A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF AGMB-129 IN PATIENTS WITH FIBROSTENOTIC CROHN’S DISEASE: INTERIM RESULTS FROM THE STENOVA TRIAL
Date
May 6, 2025
Explore related products in the following collection:
